The continued increase in NTM lung infections among pwCF represents a public health and clinical burden of NTM in the U.S. Although increased uptake of CFTR modulator therapies, such as Trikafta® appears to have resulted in a decreased risk of NTM lung infections among pwCF, continued surveillance for NTM lung infections is needed in both the CF and non-CF populations to assess the burden of these infections and evaluate trends. Here, CFTR is linked to cystic fibrosis.